Annexon, Inc. Share Price
ANNXAnnexon, Inc. Stock Performance
Open $5.33 | Prev. Close $5.56 | Circuit Range N/A |
Day Range $4.98 - $5.64 | Year Range $2.03 - $7.16 | Volume 1,69,958 |
Average Traded $5.42 |
Annexon, Inc. Share Price Chart
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
21-Jul-26 | $5.33 | $5.38 | +0.00% |
21-Jul-26 | $5.33 | $5.38 | -3.15% |
20-Jul-26 | $5.83 | $5.56 | -3.81% |
17-Jul-26 | $5.83 | $5.78 | -1.78% |
16-Jul-26 | $6.41 | $5.88 | -9.53% |
15-Jul-26 | $5.94 | $6.50 | +17.42% |
14-Jul-26 | $5.66 | $5.54 | -1.42% |